Financials Xencor, Inc.

Equities

XNCR

US98401F1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
19.98 USD +3.90% Intraday chart for Xencor, Inc. +8.71% -5.89%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,951 2,507 2,346 1,560 1,292 1,232 - -
Enterprise Value (EV) 1 1,421 1,904 2,012 933.5 553.1 755.7 1,232 1,232
P/E ratio 74.8 x -36.1 x 29.3 x -28 x -10.2 x -5.98 x -7.22 x -12.5 x
Yield - - - - - - - -
Capitalization / Revenue 12.4 x 20.4 x 8.53 x 9.48 x 7.68 x 13.2 x 7.9 x 4.64 x
EV / Revenue 9.07 x 15.5 x 7.31 x 5.67 x 3.29 x 8.1 x 7.9 x 4.64 x
EV / EBITDA 78.4 x -26.8 x 39.3 x -12.7 x -4.35 x -4.19 x -7.84 x -9.29 x
EV / FCF 24.9 x -122 x -66.7 x -66.6 x 8.3 x -3.55 x -5.78 x -
FCF Yield 4.01% -0.82% -1.5% -1.5% 12.1% -28.2% -17.3% -
Price to Book 3.3 x - - - - - - -
Nbr of stocks (in thousands) 56,721 57,455 58,482 59,924 60,875 61,647 - -
Reference price 2 34.39 43.63 40.12 26.04 21.23 19.98 19.98 19.98
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 156.7 122.7 275.1 164.6 168.3 93.25 155.9 265.7
EBITDA 1 18.12 -71 51.26 -73.67 -127.1 -180.5 -157.1 -132.6
EBIT 1 13.82 -76.8 43.77 -82.47 -138.6 -214.6 -188 -103.9
Operating Margin 8.82% -62.59% 15.91% -50.11% -82.36% -230.17% -120.57% -39.09%
Earnings before Tax (EBT) 1 27.19 -69.33 82.63 -54.51 -120.4 -194.2 -169 -92.4
Net income 1 26.88 -69.33 82.63 -55.18 -126.1 -203.9 -171.5 -99.94
Net margin 17.15% -56.51% 30.04% -33.53% -74.9% -218.68% -109.99% -37.61%
EPS 2 0.4600 -1.210 1.370 -0.9300 -2.080 -3.339 -2.769 -1.598
Free Cash Flow 1 57.02 -15.54 -30.15 -14.01 66.66 -213 -213 -
FCF margin 36.39% -12.67% -10.96% -8.51% 39.6% -228.41% -136.64% -
FCF Conversion (EBITDA) 314.65% - - - - - - -
FCF Conversion (Net income) 212.17% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 19.68 154 85.5 30.18 27.3 21.61 18.96 45.52 59.16 44.69 24.99 24.52 24.62 25.6 34.11
EBITDA 1 -39.31 93.76 28.64 -25.78 -36.11 -40.43 -57.12 -23.11 -15.13 -30.4 -28.34 -28.33 -28.71 -29.26 -32.81
EBIT 1 -41.3 91.65 26.47 -28 -38.35 -42.59 -59.36 -26 -18.27 -33.63 -49.57 -52.24 -53.58 -52.45 -46.52
Operating Margin -209.83% 59.51% 30.96% -92.79% -140.47% -197.1% -313.07% -57.11% -30.88% -75.25% -198.34% -213.02% -217.6% -204.9% -136.4%
Earnings before Tax (EBT) 1 -40.19 73.06 23.59 -33.98 -31.67 -12.46 -60.76 -21.95 -24.27 -13.45 -44.73 -47.14 -51.43 -50.79 -44.78
Net income 1 -40.19 73.06 23.59 -33.98 -32.76 -12.04 -60.76 -21.95 -24.27 -19.1 -47.58 -49.39 -52.87 -51.97 -44.78
Net margin -204.19% 47.44% 27.6% -112.59% -120% -55.72% -320.45% -48.23% -41.02% -42.74% -190.38% -201.39% -214.71% -203% -131.27%
EPS 2 -0.6900 1.210 0.3900 -0.5700 -0.5500 -0.2000 -1.020 -0.3700 -0.4000 -0.3100 -0.7782 -0.8049 -0.8625 -0.8476 -0.7900
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/8/21 2/23/22 5/5/22 8/3/22 11/7/22 2/23/23 5/8/23 8/3/23 11/7/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 530 603 334 627 739 476 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 57 -15.5 -30.2 -14 66.7 -213 -213 -
ROE (net income / shareholders' equity) - - - -7.55% -18.1% -30.6% -30.9% -
ROA (Net income/ Total Assets) - - - -6.55% -14% -27% -27.3% -
Assets 1 - - - 842.2 899.5 755.2 627 -
Book Value Per Share 10.40 - - - - - - -
Cash Flow per Share 2 1.100 - - - 1.410 -5.060 -1.160 -
Capex 1 7.35 10.5 13.3 38.5 18.4 39 43 -
Capex / Sales 4.69% 8.59% 4.83% 23.39% 10.96% 41.82% 27.58% -
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.98 USD
Average target price
36.18 USD
Spread / Average Target
+81.09%
Consensus
  1. Stock Market
  2. Equities
  3. XNCR Stock
  4. Financials Xencor, Inc.